These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9423286)
1. Functional analysis of mouse keratin 8 in polyoma middle T-induced mammary gland tumours. Baribault H; Wilson-Heiner M; Muller W; Penner J; Bakhiet N Transgenic Res; 1997 Nov; 6(6):359-67. PubMed ID: 9423286 [TBL] [Abstract][Full Text] [Related]
2. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression. Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046 [TBL] [Abstract][Full Text] [Related]
3. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Roussos ET; Wang Y; Wyckoff JB; Sellers RS; Wang W; Li J; Pollard JW; Gertler FB; Condeelis JS Breast Cancer Res; 2010; 12(6):R101. PubMed ID: 21108830 [TBL] [Abstract][Full Text] [Related]
4. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis. Zuo Y; Ulu A; Chang JT; Frost JA Breast Cancer Res; 2018 May; 20(1):41. PubMed ID: 29769144 [TBL] [Abstract][Full Text] [Related]
5. Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment. Dong S; Ruiz-Calderon B; Rathinam R; Eastlack S; Maziveyi M; Alahari SK Int J Cancer; 2020 May; 146(9):2576-2587. PubMed ID: 31525254 [TBL] [Abstract][Full Text] [Related]
6. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Gorska AE; Jensen RA; Shyr Y; Aakre ME; Bhowmick NA; Moses HL Am J Pathol; 2003 Oct; 163(4):1539-49. PubMed ID: 14507660 [TBL] [Abstract][Full Text] [Related]
7. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53. Hosokawa Y; Papanikolaou A; Cardiff RD; Yoshimoto K; Bernstein M; Wang TC; Schmidt EV; Arnold A Transgenic Res; 2001 Oct; 10(5):471-8. PubMed ID: 11708657 [TBL] [Abstract][Full Text] [Related]
8. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Bocchinfuso WP; Hively WP; Couse JF; Varmus HE; Korach KS Cancer Res; 1999 Apr; 59(8):1869-76. PubMed ID: 10213494 [TBL] [Abstract][Full Text] [Related]
9. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Krane IM; Leder P Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899 [TBL] [Abstract][Full Text] [Related]
10. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086 [TBL] [Abstract][Full Text] [Related]
11. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Zinser GM; Welsh J Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467 [TBL] [Abstract][Full Text] [Related]
13. Transgenic mice bearing the polyomavirus large T antigen directed by 2.1 kb of the keratin 19 promoter develop bronchiolar papillary tumors with progression to lung adenocarcinomas. Lebel M; Webster M; Muller WJ; Royal A; Gauthier J; Mes-Masson AM Cell Growth Differ; 1995 Dec; 6(12):1591-600. PubMed ID: 9019164 [TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis. Jahchan NS; You YH; Muller WJ; Luo K Cancer Res; 2010 May; 70(10):4204-13. PubMed ID: 20460516 [TBL] [Abstract][Full Text] [Related]
17. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Guy CT; Cardiff RD; Muller WJ Mol Cell Biol; 1992 Mar; 12(3):954-61. PubMed ID: 1312220 [TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Sevenich L; Schurigt U; Sachse K; Gajda M; Werner F; Müller S; Vasiljeva O; Schwinde A; Klemm N; Deussing J; Peters C; Reinheckel T Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2497-502. PubMed ID: 20133781 [TBL] [Abstract][Full Text] [Related]
19. Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene. Robinson GW; Wagner KU; Hennighausen L Oncogene; 2001 Oct; 20(48):7115-9. PubMed ID: 11704837 [TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Ritland SR; Rowse GJ; Chang Y; Gendler SJ Cancer Res; 1997 Aug; 57(16):3520-5. PubMed ID: 9270023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]